The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

banner

Covalon Licenses Intellectual Property to Prevent Ventilator-Associated Pneumonia from the University of Michigan

09-Feb-2016 | Source : AG-IP News | Visits : 6211
MISSISSAUGA, Ontario - Covalon Technologies Ltd., an advanced medical technologies company, has announced in a press release a licensing agreement with the University of Michigan’s Center for Integrative Research in Critical Care (“MCIRCC”), whereby Covalon has licensed intellectual property from MCIRCC that, when commercialized, could prevent or reduce the occurrence of Ventilator-Associated Pneumonia (“VAP”), a potentially devastating hospital acquired infection, and the most common nosocomial infection in critically ill patients.
 
Covalon has commenced the development of a product prototype, based on work performed by Dr. Kevin Ward at MCIRCC and colleagues at Virginia Commonwealth University.  This work formed the basis for the patents and intellectual property licensed by Covalon.  The commercialized product is expected to be inserted into a ventilated patient’s mouth, regardless of the brand of endotracheal tube or ventilator used, to provide antimicrobial protection against the pathogens commonly associated with VAP. 
 
Hospital acquired pneumonia can occur in both mechanically ventilated and non-ventilated patients, and can greatly extend their hospital stay, resulting in mortality rates of up to 50% of critically ill patients who acquire VAP while in intensive care. VAP occurs in as much as 65% of mechanically ventilated ICU patients and has an average cost of $40,000 per episode to US hospitals to treat. 
 
“VAP affects the most vulnerable of patients and many symptoms typically associated with pneumonia are masked or absent because patients are often sedated and unable to communicate,” stated Dr. Ward.  “Patients requiring mechanical ventilation quickly become colonized with dangerous bacteria found in hospitals.  In addition, many of these patients are immunocompromised.  It’s these conditions that make VAP difficult, controversial and expensive with regard to clinical diagnosis, treatment plans and prevention strategies.”
 
Despite an increased understanding of the disease-causing bacteria and diagnosis of VAP, prevention remains problematic because current solutions require resource intensive activities with an already complex patient load and/or expensive equipment that is not standardized or readily available in all patient care environments or care facilities.  Covalon’s commercialization efforts related to this technology are focused on developing an antimicrobial device that is universally applicable to patients who are ventilated or at risk of developing VAP.
 
“We know that VAP prevention strategies include reduction of bacterial colonization and aspiration avoidance.” stated Covalon CEO Brian Pedlar. “By combining Covalon’s extensive experience in developing leading antimicrobial medical devices and MCIRCC’s intellectual property, we are confident that our development work will lead to reduced costs incurred by hospitals, more effective use of the clinician’s time, and most importantly better patient outcomes.”
 
“Timing is difficult to assess with early stage projects, but Covalon has a proven track record of developing products and bringing them to market.” said Pedlar.
 
Covalon’s other infection fighting technologies include the IV Clear™ and SurgiClear™ lines of dual antimicrobial silicone adhesive products, and it recently announced FDA clearance of their new SilverCoat Foley designed to help combat urinary tract infections, the most frequently diagnosed hospital acquired infection.
 
share



Related Articles